Lupin Launches Generic Sugammadex Injection After U.S. FDA Approval

MUMBAI — Global pharmaceutical leader Lupin Limited announced the U.S. Food and Drug Administration (U.S. FDA) approval and commercial launch of its generic Sugammadex Injection in the United States. The announcement, disclosed on July 30, 2026, marks the launch of a key bioequivalent alternative to Merck’s reference drug Bridion®, expanding treatment options for surgical patients requiring anesthesia reversal across hospitals and surgical centers.

The regulatory clearance for the Abbreviated New Drug Application (ANDA) covers two single-dose vial strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL). The commercial rollout strengthens Lupin’s growing portfolio of complex generic injectables in North America, a key revenue driver for the company.

Therapeutic Role and Clinical Application of Sugammadex Injection

Sugammadex Injection is a specialized agent indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgical procedures. The therapy is approved for use in both adult patients and pediatric patients aged 2 years and older.

During general anesthesia, muscle relaxants such as rocuronium or vecuronium are routinely administered to facilitate endotracheal intubation and maintain muscle relaxation during surgery. Sugammadex works by encapsulating these neuromuscular blocking agents in the plasma, rapidly reversing muscle relaxation and enabling patients to regain spontaneous breathing and motor function safely post-surgery.

+---------------------------------------------------------------------------------+
|               LUPIN SUGAMMADEX INJECTION: PRODUCT SPECIFICATIONS               |
+---------------------------------------------------------------------------------+
|  Product Name             | Sugammadex Injection                               |
|  Brand Reference          | Bioequivalent to Bridion® (Merck & Co., Inc.)      |
|  Dosage Strengths         | 200 mg/2 mL (100 mg/mL) & 500 mg/5 mL (100 mg/mL)  |
|  Formulation              | Single-Dose Vial for Intravenous Administration    |
00|  Approved Indication      | Reversal of Rocuronium & Vecuronium Blockade     |
|  Target Patient Base      | Adults and Pediatric Patients (Aged 2+ Years)      |
+---------------------------------------------------------------------------------+

Market Significance and Strategic Impact for Lupin   

The launch of generic Sugammadex Injection targets a high-value clinical segment in the U.S. hospital system. Bridion® has long remained a widely utilized drug in operating rooms across North America for rapid recovery from anesthesia. By delivering an FDA-approved generic version, Lupin provides healthcare systems with a cost-effective alternative while capturing market share in specialized injectables.

The commercial expansion aligns with Lupin’s overall financial growth in North America. In its recent Q4 FY26 earnings release, Lupin reported a 32.9% year-on-year increase in consolidated net sales to ₹7,391.91 crore, driven by a 55% surge in North American sales to ₹3,514.5 crore. Expanding generic injectable offerings remains vital for sustained operational profitability across hospital networks.

Regulatory Compliance and Corporate Governance

Lupin submitted formal regulatory filings regarding the U.S. FDA approval and product launch under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosures were communicated directly to major stock exchanges, including the BSE Limited and the National Stock Exchange of India Limited.

Headquartered in Mumbai, Lupin operates 15 manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals. The company holds established positions across therapy areas including respiratory, central nervous system, cardiovascular, anti-infective, and complex generics.

Official Sources Section

According to official disclosures, regulatory notifications, and corporate filings submitted to market authorities:

• Corporate filings submitted to the
  BSE Limited
  and
  National Stock Exchange of India Limited
  under statutory compliance guidelines.

• Product regulatory status documentation issued by the
  United States Food and Drug Administration
  .

• Official press announcements published by
  Lupin Limited

Quote Section

According to official company regulatory disclosures submitted by corporate executives:

"Lupin Limited has received approval from the U.S. FDA for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL single-dose vials, bioequivalent to Merck's Bridion® Injection. The product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery."

Why It Matters

The availability of generic Sugammadex Injection provides U.S. hospitals, surgical centers, and anesthesiologists with greater supply choice and reduced procurement costs for a vital operating room drug. For investors and healthcare analysts, the launch underscores Lupin's execution capability in bringing complex, high-value generic injectables to market, reinforcing its competitive position in North American pharmaceutical distribution.

Key Facts at a Glance

• Product: Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials.

• Regulatory Milestone: U.S. FDA approval and commercial U.S. launch.

• Reference Brand: Bioequivalent to Merck's Bridion® Injection.

• Target Application: Reversal of neuromuscular blockade in surgical patients aged 2 years and older.

• Market Geography: Distributed across hospitals and clinical healthcare facilities in the United States.

Frequently Asked Questions (FAQ)

What is Sugammadex Injection used for in surgery?

Sugammadex Injection is used by medical professionals to reverse neuromuscular blockade caused by muscle relaxants (rocuronium bromide and vecuronium bromide) administered during surgical procedures under anesthesia.

Which product is Lupin’s Sugammadex Injection generic to?

Lupin’s Sugammadex Injection is approved by the U.S. FDA as a direct bioequivalent to Merck’s reference listed drug, Bridion® Injection.

What dosage forms of Sugammadex Injection are available?

The medication is supplied in single-dose vials in two dosage strengths: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL).

Who can receive Sugammadex Injection?

The treatment is FDA-approved for both adult patients and pediatric patients aged 2 years and older undergoing surgical procedures requiring anesthesia reversal.

Source: Lupin Limited Disclosures, U.S. Food and Drug Administration, BSE Limited Filings, and National Stock Exchange of India Limited.